NeuroMetrix — Investor Presentation (October 2016)
17 slides from NeuroMetrix's investor presentation, Oct 31, 2016
Slide 1: NeuroMetrix Investor Presentation, November 2016
Nasdaq : NURO Shai N. Gozani, MD, PhD Tom Higgins President & CEO Chief Financial Officer November 2016
Slide 2: Overview
Overview • Boston based healthcare company • Founded in 1996 as spin - off from MIT • Integrate bioelectrical and digital medicine to address chronic disease • Premier R&D capabilities • Experienced commercialization team • Market a first - in - class over - the - counter wearable device to treat ch
Slide 3: Chronic Pain Market: Large Opportunity with Many Unmet Needs
Chronic Pain Market Large Opportunity with Many Unmet Needs • 100M US adults, 1.5B worldwide – Low back pain, arthritis, diabetic nerve pain, fibromyalgia, cancer, CRPS, PHN, neck pain, facial pain • $600B annual cost in US 1 • $35B global market 2 • $20B annual out - of - pocket spending in US 3 •
Slide 4: Quell Wearable Technology
Quell Wearable Technology • Wearable neurostimulator • Widespread chronic pain relief • Safe, no significant side effects • Can be used 24/7 • App enabled • Monitors therapy and health metrics 4 NeuroMetrix, Inc. ©2016
Slide 5: Quell Provides Therapeutic Benefit to ~80% of Subjects
Quell Provides Therapeutic Benefit to 70 - 80% of Subjects • 81% of subjects reported improvement in chronic pain • 67% of subjects reported reduction in pain medication use 5 NeuroMetrix, Inc. ©2016 Gozani. Fixed - Site High - Frequency Transcutaneous Electrical Nerve Stimulation for Treatment of C
Slide 6: Ongoing Quell Clinical Studies
Ongoing Quell Clinical Studies 6 NeuroMetrix, Inc. ©2016 Title Location(s) Design Status Quell TENS band for Chemotherapy - Induced Peripheral Neuropathy University of Rochester School of Medicine Open Label (N=30) 50% enrolled Q2 ‘17 readout Quell Opioid Reduction and Pain Relief in Patients With C
Slide 7: Market Opportunity of 19M Chronic Pain Sufferers
Market Opportunity of 19M Chronic Pain Sufferers 7 100M 19M Market opportunity estimate independently developed by Connelly Partners (Boston, MA) using Nielsen MRI data. 2016. • Not migraine or headache • 40+ years of age • $75K+ household income • College educated • Active • Want to minimize use of
Slide 8: Quell Pricing
Quell Pricing 8 NeuroMetrix, Inc. ©2016 Quell Starter Kit $249 Replacement Electrodes $29.95
Slide 9: North America Quell Distribution
North America Quell Distribution 9 Consumer Professional e - commerce Retail (1500 stores) TV QuellRelief.com Chiro /PT Direct WBC Group NeuroMetrix, Inc. ©2016 Physicians Institutional (VA)
Slide 10: Quell Demonstrating Consistent Growth
Quell Demonstrating Consistent Growth 10 NeuroMetrix, Inc. ©2016 $602 $985 $1,478 $1,703 $2,534 $2,900 0 500 1000 1500 2000 2500 3000 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 Invoiced Sales GAAP Revenue Deferred Revenue Sales & Revenue ($1000s) 2,607 4,514 6,675 8,138 11,201 12,086 0 2000 400
Slide 11: Consumers Report Positive Experience With Quell
Consumers Report Positive Experience With Quell 11 NeuroMetrix, Inc. ©2016 1 2 3 4 5 >100 Reviews <100 Reviews Expected Tabulated August 27, 2016 Expected average rating based on clinical efficacy and return rate (75% with 4 or 5 stars and 25% with 1 or 2 stars). Average Customer Satisfaction Rating
Slide 12: Quell has Limited Direct Competition
Quell has Limited Direct Competition • Many OTC and Rx options for chronic pain • Attractive space so constant flow of new products and entrants • Chronic pain sufferers utilize multiple treatments (“toolbox”) • Quell is only wearable designed and powered for chronic pain • Quell stands out on effic
Slide 13: Quell is More Powerful than OTC TENS
0.1 1 10 100 1000 0 20 40 60 80 100 Energy ( mW - h) Stimulation Current (mA) Quell OTC TENS 5x Quell is More Powerful than OTC TENS • Quell generates 5x greater energy at same stimulation current • Quell has 15x greater maximum energy 15x Therapy Energy per Session Energy requirements for half of Q
Slide 14: Upcoming Catalysts
Upcoming Catalysts 14 NeuroMetrix, Inc. ©2016 Q4’16 • DPNCheck China launch • Quell CE mark Q1’17 • CES • Quell retail expansion Q2’17 • Quell EU launch Q3’17 • Scripps study readout Q4’17 • BWH study readout
Slide 15: Financials
Financials 15 NeuroMetrix , Inc. ©2016 Outstanding 5,318,273 Preferred, as-converted 10,982,929 16,301,202 Recent Closing Price $1.36 Market Value $22,169,635 Market Valuation (Oct 26, 2016) ($000's) Q3 2016 Q2 2016 Q1 2016 2015 2014 2013 Revenue $3,389 $2,647 $2,275 $7,300 $5,513 $5,279 - Quell $2,
Slide 16: Management Team
Shai N. Gozani, MD., PhD. President, CEO and Founder Thomas T. Higgins SVP and CFO Frank McGillin SVP and General Manager, Consumer Management Team 16 NeuroMetrix, Inc. ©2016 • Extensive public company CFO experience • Strong operational background • 20+ years consumer health care experience • Deep
Slide 17: Investment Highlights
Investment Highlights • Commercial stage healthcare company combining bioelectrical and digital medicine to address chronic disease • Market a first - in - class over - the - counter wearable device to treat chronic pain • Razor/razor - blade business model with good sales growth in first 6 quarters